

China Emergency Guidelines Recommend USCOM for Acute Heart Failure Monitoring

- USCOM included for emergency monitoring of HF in China ED's
- Four major Chinese ED academies endorsed HF guidelines
- 12.1m patients with HF in China and growing

Tuesday 6th September 2022: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) advises that USCOM has been included in national emergency medicine guidelines for management of acute heart failure in China. The Guidelines were authored by The Chinese Society of Emergency Medicine, The Chinese Association of Emergency Physicians, Emergency Branch of China International Exchange and Promotive Association for Medical and Healthcare, and The Professional Committee of Emergency Medicine of the People's Liberation Army.

Background:

Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality, an accompanying high re-admission rate, poor prognosis and increasing prevalence. The earlier HF is detected and the more precise the treatment the shorter and less serious the acute phase of the disease, and the less time for hospitalisation and less cost. Worldwide the trend is increasingly toward effecting early management of HF, and that starts in emergency departments. The more precise the monitoring technology, the more rapid the diagnosis and the less time of hospitalisation. While invasive technologies have previously been preferred, increasingly non-invasive technologies are recognised as accurate, safe and convenient to use, with better patient acceptance and rapid delivery of cardiovascular parameters. The data from the China Heart Failure Center program showed the suboptimal prescription of guideline-recommended treatment of HF during hospitalization was related to increased readmission and poor prognosis, while the promotion of guideline-recommended management is critical to improve clinical outcomes and reduce the economic burden.

USCOM 1A is a specialised non-invasive ultrasonic haemodynamic monitor with established validation in HF and precise care of cardiovascular abnormalities. USCOM 1A is also established in a number of other practice guidelines for diagnosis and management of cardiac disease in adults and children. Its non-invasive nature and high accuracy make it particularly useful for application in emergency departments world-wide.

Facts:

HF has an incidence on China of ~1.1%, and occurs in a reported 12.1m patients. The mean cost of HF care per year is estimated at \$4,406.80 USD per patient making HF a serious public health burden in China. From 2007 to 2017 China's ED's attendances increased 300% from 51.9m to 166.5m visits, while ED beds increased from 10,783 to 42,367, up 300%.

Commentary:

Executive Chairman of Uscom, Professor Rob Phillips said *"This recognition by the collaborative colleges of emergency medicine in China is important for Uscom as we further consolidate our role in clinical practice across China. USCOM 1A was also recommended by the PRC Ministry of Health and Medical Commission for the treatment of severe COVID. These clinical practice guidelines reflect years of data and clinician confidence and confirm the scientific leadership that Uscom has established with its products world-wide.*

China is the fastest evolving medical market in the world, with a large discriminating population having high expectations of quality health care. Uscom is invested in China with a Beijing based subsidiary and has been recognised as a National High Technology Enterprise by a branch of the Chinese Ministry of Science and Technology. The Chinese market has been difficult over the last 2 years with COVID lockdowns and regulatory changes, and these guidelines will provide clinical support for our sales teams in this exceedingly large market. Additionally, in preparation for a China rebound and increased global growth, Uscom is mid establishment of its new manufacturing and R&D centre in Beijing in a partnership with the world's largest precision electronics manufacturer and largest employer in China, Foxconn."

References:

Committee of Emergency Branch of China International Exchange and Promotive Association for Medical and Healthcare, Chinese Society of Emergency Medicine, Chinese Association of Emergency Physicians, Professional Committee of Emergency Medicine of the People's Liberation Army. Guideline for emergency management of acute heart failure in China (2022). Journal of Clinical Emergency (China), 2022; 31(8): 1016-1041.

Wang H, Chai K, Du M, et al. Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis. Circ Heart Fail 2021;14(10):e008406. doi: [10.1161/CIRCHEARTFAILURE.121.008406](https://doi.org/10.1161/CIRCHEARTFAILURE.121.008406)

Pan C, Pang JJ, Cheng K, et al. Trends and challenges of emergency and acute care in Chinese mainland: 2005-2017. World J Emerg Med 2021; 12(1): 5-11. doi: [10.5847/wjem.i.1920-8642.2021.01.001](https://doi.org/10.5847/wjem.i.1920-8642.2021.01.001)



Uscom
ASX RELEASE

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.